Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 5/20 | 0.43 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | MITF | O75030 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 5/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | MAOB | P27338 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 3/20 | 0.38 |
| ▸ | POLB | P06746 | 2/20 | 0.38 |
| ▸ | MET | P08581 | 3/20 | 0.37 |
| ▸ | IGF1R | P08069 | 1/20 | 0.37 |
| ▸ | BLM | P54132 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6219646 | 0.89 | LMNA (0.44) | LMNARXFP1SMN1; SMN2MAPTGAA | |
| Hydrochloric Acid SCHEMBL6225831 | 0.88 | LMNA (0.43) | LMNARXFP1SMN1; SMN2MAPTGAA | |
| SCHEMBL6221743 | 0.85 | LMNA (0.44) | LMNARXFP1SMN1; SMN2MAPTGAA | |
| SCHEMBL7420636 | 0.84 | SMN1; SMN2 (0.47) | LMNARXFP1SMN1; SMN2MITFGAA | |
| SCHEMBL6221585 | 0.80 | MAPT (0.43) | LMNASMN1; SMN2MAPTGAARAB9A | |
| Hydrochloric Acid SCHEMBL6220700 | 0.79 | MAPT (0.42) | LMNASMN1; SMN2MAPTGAARAB9A | |
| SCHEMBL6221217 | 0.79 | MAPT (0.42) | LMNASMN1; SMN2MAPTRAB9APOLB | |
| SCHEMBL7418952 | 0.78 | RAB9A (0.44) | LMNASMN1; SMN2GAARAB9A | |
| Hydrochloric Acid SCHEMBL6220813 | 0.78 | MAPT (0.41) | LMNASMN1; SMN2MAPTRAB9APOLB | |
| SCHEMBL6219843 | 0.78 | MAPT (0.41) | LMNASMN1; SMN2MAPTRAB9APOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1107966-B1 | OXO-PYRIDOIMIDAZOLE-CARBOXAMIDES: GABA BRAIN RECEPTOR LIGANDS | NEUROGEN CORP (US) | 2005-07-27 | — | — | EP | claimed |
| US-6451809-B2 | COGNITION ACTIVATORS; PSYCHOLOGICAL DISORDERS | NEUROGEN CORPORATION | 2002-09-17 | — | — | US | claimed |
| US-20010011133-A1 | Oxo-pyridoimidazole-carboxamides: GABA brain receptor ligands | NEUROGEN CORPORATION. | 2001-08-02 | — | — | US | claimed |
| US-6177569-B1 | DIAGNOSIS AND TREATMENT OF ANXIETY, DOWN SYNDROME, DEPRESSION, SLEEP, COGNITIVE AND SEIZURE DISORDERS, OVERDOSE WITH BENZODIAZEPINE DRUGS AND FOR ENHANCEMENT OF ALERTNESS | NEUROGEN CORPORATION | 2001-01-23 | — | — | US | claimed |
| EP-1107966-B1 | OXO-PYRIDOIMIDAZOLE-CARBOXAMIDES: GABA BRAIN RECEPTOR LIGANDS | NEUROGEN CORP (US) | 2005-07-27 | — | — | EP | disclosed |
| US-6451809-B2 | COGNITION ACTIVATORS; PSYCHOLOGICAL DISORDERS | NEUROGEN CORPORATION | 2002-09-17 | — | — | US | disclosed |
| US-20010011133-A1 | Oxo-pyridoimidazole-carboxamides: GABA brain receptor ligands | NEUROGEN CORPORATION. | 2001-08-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010011133-A1 | Oxo-pyridoimidazole-carboxamides: GABA brain receptor ligands | GABRA1, GABRA4, GABRB1 | LMNA 1816/4885RXFP1 170/4885SMN1; SMN2 1024/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.